Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Multivariate proportional hazard ratios

From: Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas

Parameter Hazard Ratio Lower 95% Upper 95% P value
Primary Cohort
 ALC < 600 vs. ≥600 3.65 1.05 12.98 0.04
 L% < 9 vs. ≥9 9.68 2.91 37.62 0.0002
 NLR ≥7 vs. < 7 14.74 4.14 63.96 < 0.0001
Expanded Cohort
 ALC < 600 vs. ≥600 4.89 1.90 12.90 0.001
 L% < 9 vs. ≥9 5.55 2.13 15.72 0.0004
 NLR ≥7 vs. < 7 4.69 1.99 11.72 0.0004
  1. Multivariate analyses were adjusted for the following independent variables: age, gender, race, smoking history, primary site of cancer, viral association, ECOG performance status, number of prior lines of therapy, and immunotherapy regimen; ALC Absolute lymphocyte count, L% Lymphocyte %, NLR Neutrophil-lymphocyte ratio